News
These 3 Stocks Look Expensive, but Are Actually Cheap
Stocks with above average price-to-earnings (P/E) ratios, or those trading near their 52-week highs, aren't always expensive. The true test of whether a stock is cheap or not, after all, is the....
How Good Is AbbVie's Humira Deal With Amgen?
One major cloud that has been hanging over AbbVie (NYSE: ABBV) is how long the company will be able to hold off biosimilar competition for its top-selling drug Humira. Amgen (NASDAQ: AMGN) won FDA....
Why BlackBerry, AbbVie, and bluebird bio Jumped Today
Thursday was a quiet day on Wall Street, with major benchmarks remaining close to the unchanged level. Sentiment among market participants remained relatively favorable in the aftermath of the....
Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio
This version of our ongoing better buy series pits two development-stage biotechs, Bellicum Pharmaceuticals (NASDAQ: BLCM) and bluebird bio (NASDAQ: BLUE), against each other. The companies have....
This Drug Pricing Scheme Could Be Making Your Medicine More Expensive
Biosimilars that are as safe and effective as expensive brand-name biologics could significantly reduce drug prices and healthcare spending, but only if they win support from insurers.....
Here's Why Spectrum Pharmaceuticals, Inc. Is Surging Today
Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), a biopharmaceutical company primarily focused on cancer and blood-based disorders, are rising in response to some surprising early stage....
Why Advanced Accelerator Application SA Stock Jumped Higher Today
Shares of Advanced Accelerator Application (NASDAQ: AAAP) are up 12% as of 11:23 a.m. EDT after Bloomberg reported that Novartis (NYSE: NVS) is considering acquiring the radiopharmaceutical....
Why DexCom Stock Is Getting Crushed Today
Shares of medical device company and diabetes specialist DexCom Inc. (NASDAQ: DXCM) slipped sharply Thursday morning, declining by more than 36% as of 11:50 a.m. EDT. This tumble stemmed from the....
Vertex Pharmaceuticals: The Gilead Sciences of Cystic Fibrosis?
In only a year, Vertex Pharmaceuticals (NASDAQ: VRTX) has grown from a market cap of around $20 billion to knocking on the door of a $40 billion market cap. The biotech isn't finished growing.....
This Marijuana Stock May Already Be Running Out of Chances to Succeed
In case you haven't noticed, the marijuana industry is growing by leaps and bounds. According to cannabis research firm ArcView, the legal weed industry in North America is estimated to grow by....
Why Aurinia Pharmaceuticals Could Be a Gold Mine for Growth Investors
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) stock has already tripled this year, on renewed hopes of success for an experimental lupus treatment. Despite this year's big run-up, this....
5 Drugs That Could Make Celgene the Best Biotech Stock of the Next Decade
Over the past five years, Celgene (NASDAQ: CELG) stock has soared 280%. That's better than any other biotech with a market cap of $50 billion or more.Celgene's past success stemmed primarily from....
3 Top Stocks in Healthcare
Healthcare stocks are hot this year. The sector-tracking iShares S&P Global Healthcare index has already tacked on a 17% gain this year.If you're looking to catch a ride on the healthcare....
Johnson & Johnson Investors, Mark Your Calendars for October
After a nice jump in the first half of 2017, Johnson & Johnson (NYSE: JNJ) stock has largely tread water over the last few months. Wouldn't it be nice if the healthcare giant had a catalyst or....
Axovant Sciences' Alzheimer's Disease Trial Comes Up Empty -- What Now?
Historically, 99% of Alzheimer's disease drugs to enter clinical trials have failed, yet Axovant Sciences (NASDAQ: AXON) believed it could design a phase 3 trial for its Alzheimer's disease drug,....
ALPHA MOS : INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE
INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS PREVUES PAR L'ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L'ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AUTORITE DES MARCHES....
Here's Why PTC Therapeutics, Inc. Is Slipping Today
Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) have fallen 17.3% as of 11:53 a.m. EDT on Tuesday. Recently released briefing documents left investors even less hopeful an upcoming independent....
3 Biotech Stocks With Major Catalysts in October
Every month brings plenty of catalysts for several biotech stocks. October is no exception. There are quite a few regulatory decisions and clinical results expected to be announced next....
The Creative Ways Drugmakers Are Delaying Generics
Drugmakers are increasingly embracing new tactics to protect billions of dollars in sales from generic competition. These strategies often involve patent trials, but that's not the only way....
3 Reasons to Buy the Dip With Exelixis
In just two days, Exelixis (NASDAQ: EXEL) has lost over 15% of its market cap. The tumble for the once-hot biotech stock started last week with a downgrade of the stock by an analyst at Leerink....
Caveat Emptor When Buying High-Yield Drug Stocks
Income investors seemingly have hundreds of stocks to choose from that currently pay a dividend. The telecom and utility sectors often generate some of the most robust payouts for investors, with....
How Low Does Valeant Pharmaceuticals' Debt Really Need to Go?
There's as much of a chance that Valeant Pharmaceuticals (NYSE: VRX) wipes out its debt of nearly $28.5 billion anytime soon as there is of Donald Trump receiving a birthday present from football....
5 Numbers That Should Get MannKind Investors Excited
MannKind (NASDAQ: MNKD) hasn't exactly given investors a whole lot to get excited about in recent years. That could be changing, though. Since May, MannKind stock has soared more than 130% and now....
3 Bargain Biotech Stocks You Can Buy Today
You might have heard that the stock market is overpriced after years of solid gains. And it is. That doesn't mean every stock is overpriced, though.Actually, several biotech stocks look....
Why Celldex Therapeutics, Inc. Jumped Higher Today
Celldex Therapeutics (NASDAQ: CLDX) closed on Monday up 12.8%, with no apparent news to justify the double-digit gain by the biotech company.The move follows an 8.1% jump on Friday. Sometimes,....